­
medigraphic.com
ISSN 0188-2198 (Print)

2004, Number 1

<< Back Next >>

Rev Mex Cardiol 2004; 15 (1)

Renal artery stenting in patients payees arterial renal stenosis: Experience of an hospitable centre. Current follow-up to long term

Palacios RJM, De La Cruz RO, Bazzoni RA, Reyes DS

Language: Spanish
References: 40
Page: 14-22
PDF size: 186.24 Kb.


ABSTRACT

Background: To evaluate the safety, efficacy and the effect of renal artery stenting (RAS) in patients (pts) payees arterial renal stenosis (ARS). We show ours experience in 81 pts Payees ARS whom undergoing transluminal angioplasty with stent. Methods: From April 2000 to Nov 2003 81 pts (109 lesions) were treated in our hospital. The mean age was 66.4 + 9.8 years, 53% female, with hypertension (HA) 79%, ischuemic heart disease 91%, Diabetes Mellitus 33%, number of medications per pts 2.1 + 0.92,Unilateral (65.4%) and Bilateral (34.5%) RAS Overall, 49% lesion were ostial, all lesions were treated with stent, we used in 95% Herculink Stent (Guidant),Renal insufficiency (RI) (Cr > 1.5 mg) was present in 30 pts (37%), HA no controlled (systolic >160 mmHg, Diastolic>90 mmHg) was evident in 66.6%,60 pts was with two o more drugs antihypertensives. Results: In 25 pts (31%) payees of ARS undergoing combined revascularization all with succefull and without complications. Mean stent length was 15.3 + 2.8 mm, stent diameter 6.04 + 0.81 mm, reference vessel diameter 5.75 + 0.87 mm, the success clinical and angiographic (stenosis < 30% without death/Surgery/MI) was 97.5%, two pts undergoing renal perforation artery needed surgery. One of them death 36 h after surgery due to MI, The BP control at one years was achieved in 77% of pts. The Creatinine (Cr) wasn´t increase, before (RAS) 1.46 + 0.77 after 1.51+ 0.93 mg (p = NS) the incidence of reestenosis was at 12 months of 2.5% the follow up was done by Renal Duplex (ARS > 60%) Survival at 12 months were 90%.Conclusion: RS is a safe and effective treatment for ARS, in our study we show that 77% pts presented BP control (with less drugs) at 12 months, preservation renal function and low incidence of restenosis.


REFERENCES

  1. Gifford RW Jr. Evaluation of the hypertension patient with emphasis on detecting curable causes. Milbank Memorial Fund Q 1969; 47: 170.

  2. Davis BA et al. Prevalence of renovascular hypertension in patient with grade III or IV hypertensive retinopathy. N Engl J Med 1979; 301: 1273.

  3. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Sixth Report of the Joint National Committee on Prevention , Detection, Evaluation, and Treatment of High Blood Pressure. Arch Int Med 1997; 157: 2413-2446.

  4. Johansson M, Herlitz H, Jensen G, Rundqvist B, Friberg P. Increased cardiovascular mortality in hypertensive patients with renal artery stenosis: relation to sympathetic activation, renal function and treatment regimens. J Hypertens 1999; 17: 1743-1750.

  5. Preston RA, Epstein M. Ischemic renal disease: An emerging cause of chronic renal failure and end-stage renal disease. J Hypertens 1997; 15: 1365-1377.

  6. Rimmer JM, Gennari FJ. Atherosclerosis renovascular disease progressive renal failure. Ann Intern Med 1993: 712-719.

  7. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. The Lancet 1998; 351: 1755-1762 HOT.

  8. SHEP Cooperative Research Group. Prevention of stroke by anti hypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255-3264.

  9. Chabova V, Schirger A, Stanson AW, McKusick MA, Textor SC. Outcomes of atherosclerotic renal artery stenosis managed without revascularization. Mayo Clin Proc 2000; 75: 437-444.

  10. Caps MT, Zierler RE, Polissar NL et al. Risk of atrophy in kidneys with atherosclerotic renal artery stenosis. Kidney Int 1998; 53: 735-742.

  11. Conlon PJ, Athirakul K, Kovalik E, et al. Survival in renal vascular disease. J Am Soc Nephrol 1998; 9: 252-6.

  12. Olin JW et al. Prevalence of atherosclerotic renal artery stenosis in patients with atherosclerosis elsewhere. Am J Med 1990; 88: 46N.

  13. Mailoux LU, Bellucci AG, Mossey RT et al. Predictors of survival in patients undergoing dialysis. Am J Med 1988; 84: 855-862.

  14. Gruntzing A, Kuhlmann U, Vetter W. Treatment of renovascular hypertens with percutaneous transluminal dilatation of a renal artery stenosis. Lancet 1978; 1: 801-2.

  15. Tullis MJ, Zierler RE, Glickerman WJ, Sones PJ, Wells JO et al. Results of percutaneous transluminal angioplasty for atherosclerosis renal artery stenosis: a follow up study with duplex ultrasonography. J Vasc Surg 1997; 25: 46-54.

  16. Palmaz JC, Kapp DT, Hayashi H. Normal and stenotic renal arteries experience with balloon expandible intraluminal stenting. Radiology 1987; 161: 705-8.

  17. Bakker J, Goffette PP, Henry M et al. The ERASME study: a multi center study on the safety and technical results of the Palmaz stent used for the treatment of atherosclerotic ostial renal artery stenosis. Cardiovasc Intervent Radiol 1999; 22: 468-474.

  18. Rodriguez-Lopez JA, Werner A, Ray LI et al. Renal artery stenosis treated with stent deployment: indications, technique, and outcome for 108 patients. J Vasc Surg 1999; 29: 617-624.

  19. Cambria RP, Brewster DC, L’Italien GJ et al. The durability of different reconstructive techniques for atherosclerotic renal artery disease. J Vasc Surg 1994; 20: 76-87.

  20. Libertino JA, Bosco PJ, Ying CY et al. Renal revascularization to preserve and restore renal function. J Urol 1992; 147: 1485-7.

  21. Novick AC, Ziegelbaum M, Vidt DG, Gifford RW Jr, Pohl MA, Goormastic M. Trends in surgical revascularization for renal artery disease: ten years’ experience. JAMA 1987; 257: 498-501.

  22. Weibull H, Bergqvist D, Bergentz SE et al. Percutaneous transluminal renal angioplasty versus surgical reconstruction of atherosclerotic renal artery stenosis: a prospective randomized study. J Vasc Surg 1993; 18: 841-852.

  23. Jensen G. Renovascular hypertension New diagnostic and therapeutic procedures (review). Scand J Urol Nephrol 1995; 170(Suppl): 1-78.

  24. Sos TA. Angioplasty for the treatment of azotemia and renovascular hypertension in atherosclerosis renal a artery disease. Circulation 1991; 83: 162-66.

  25. Pickering TG, Sos TA, Vaughan ED Jr, Case DB et al. Differing patterns of renal vein renin secretion in patients with renovascular hypertension, and their role in predicting the response to angioplasty. Nephron 1986; 44 (Suppl 1): 8-11.

  26. Webster J, Marshall F, Abdalla M et al. Randomized comparison of percutaneous angioplasty vs continued medical therapy for hypertensive patients with atheromatous renal artery stenosis. J Hum Hypertens 1998; 12: 329-35.

  27. Plouin PF, Chatellier G, Darne B, Raynaud A. Blood pressure outcome of angioplasty in atherosclerotic renal artery stenosis: a randomized trial. Hypertension 1998; 31: 823-9.

  28. van Jaarsveld BC, Krijnen P, Pieterman H et al. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. N Engl J Med 2000; 342: 1007-14.

  29. Conlon PJ, Athirakul K, Kovalik E, et al. Survival in renal vascular disease. J Am Soc Nephrol 1998; 9: 252-6.

  30. Dorros G, Jaff M, Mathiak L. Four-year follow-up of Palmaz-Schatz stent revascularization as treatment for atherosclerotic renal artery stenosis. Circulation 1998; 98: 642-647.

  31. Henry M, Amor M, Chati Z. First clinical experience with the new AVE ‘Bridge’ stent in the treatment of renal stenoses [abstract]. Circulation 1998; 98: I484-I485.

  32. Rocha-Singh K, Mishkel GJ, Katholi RE. Clinical predictors of improved long-term blood pressure control after successful stenting of hypertensive patients with obstructive renal artery atherosclerosis. Cathet Cardiovasc Intervent 1999; 47: 167-172.

  33. Tuttle KR, Chouinard RF, Webber JT. Treatment of atherosclerotic renal artery stenosis with the intravascular stent. Am J Kidney Dis 1998; 32: 611-622.

  34. Rundback JH, Gray RJ, Rozenblit G. Renal artery stent placement for the management of ischemic nephropathy. J Vasc Intervent Radiol 1998; 9: 413-420.

  35. White CJ, Ramee SR, Collins TJ. Renal artery stent placement: utility in lesions difficult to treat with balloon angioplasty. J Am Coll Cardiol 1997; 30: 1445-1450.

  36. Harden PN, MacLeod Rodger RSC. Effect of renal-artery stenting on progression of renovascular renal failure. Lancet 1997; 349: 1133-1136.

  37. Henry M, Amor M, Henry I. Stent placement in the renal artery: three-year experience with the Palmaz stent. J Vasc Intervent Radiol 1996; 7: 343-350.

  38. Iannone LA, Underwood PL, Nath A. Effect of primary balloon expandable renal artery stents on long-term patency, renal function, and blood pressure in hypertensive and renal insufficient patients with renal artery stenosis. Cathet Cardiovasc Diagn 1996; 37: 243-250.

  39. Van de Ven PJG, Kaatee R, Beutler JJ. Arterial stenting and balloon angioplasty in ostial atherosclerotic renovascular disease: a randomized trial. Lancet 1999; 353: 282-286.

  40. Pache J et al. Intracoronary Stenting and Angiographic Results: Strut Thickness effect on restenosis outcome. (ISAR-STEREO) Trial J Am Coll Cardiol 2003; 41: 1285-1288.




2020     |     www.medigraphic.com

    Este sitio utiliza cookies   Estoy de acuerdo